Clinical trials
Peripheral T Cell Lymphoma clinical trials
Below are recruiting peripheral t cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 243 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Tucson, ArizonaAges 18 years+ - NCT04922567RecruitingPhase 2
Lenalidomide plus CHOP versus CHOP for untreated PTCL
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
Hangzhou, ZhejiangAges 18–75 - NCT04088422Recruiting
Blood test DNA study in mature B-cell lymphoma
This study looks at “cell-free DNA,” meaning tiny bits of DNA found in blood, in people with mature B-cell lymphoma. It may help doctors understand the disease better and how blood tests could be used to monitor it.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05444712Recruiting
Stem cell transplant after best response in some T-cell lymphomas
This trial studies whether doing an autologous stem cell transplant (using your own stem cells) after a complete response helps people with certain T-cell lymphomas stay in remission longer. It may be an option if your lymphoma has shrunk completely and you fit the safety and testing requirements.
AmiensAges 18–70 - NCT06180174RecruitingPhase 1
CD19-targeted CAR-T cells for relapsed B-cell lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05833763RecruitingPhase 2
Glosfitamab plus pirtobrutinib for mantle cell lymphoma after BTK drugs
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
Parkville, VictoriaAges 18 years+ - NCT07388563RecruitingPhase 1
Combination drug therapy for returning T-cell lymphoma
This trial tests two drugs, azacitidine and abatacept, given together for T-cell lymphoma that has come back or not improved after earlier treatment. The goal is to see if this combination can control the cancer better, potentially offering a new option for patients.
Bethesda, MarylandAges 18–120 - NCT07788118RecruitingPhase 1/Phase 2
A new car-t therapy for relapsed large b-cell lymphoma
This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.
Hangzhou, ZhejiangAges 18–75 - NCT04332822RecruitingPhase 3
Testing mini-CHOP versus adding polatuzumab for lymphoma
This study compares two lymphoma treatments: mini-CHOP alone versus mini-CHOP plus a drug called polatuzumab vedotin. It aims to see which regimen works better and is tolerable for older or frail people with certain types of aggressive B-cell lymphoma.
AlburyAges 75 years+ - NCT07750886Recruiting
Collecting samples for lymphoma research
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
Austin, TexasAges 18 years+ - NCT07730515RecruitingPhase 1/Phase 2
Study of XNW5004 plus chemo for untreated T-cell lymphoma
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06176027RecruitingPhase 1/Phase 2
New drug combo for returning AITL lymphoma
This trial tests a new combination of drugs (azacytidine plus CAOLD) for people with a specific type of T-cell lymphoma called AITL that has come back or not responded to previous treatment. The goal is to see if this treatment can work better than current options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06420076RecruitingPhase 1/Phase 2
Sequential CAR-T therapy for CD5/CD7 positive T-cell leukemia/lymphoma
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
Beijing, Beijing MunicipalityAges 2–90 - NCT07624838Recruiting
Brentuximab vedotin plus chemotherapy for CD30+ T-cell lymphoma
This study looks at how well a combination drug treatment (brentuximab vedotin plus chemotherapy) works for patients with rare T-cell lymphomas in real-world clinical practice in Spain. It focuses on patients receiving this as their first treatment.
A Coruña, A CoruñaAges 18 years+ - NCT07598578RecruitingEarly Phase 1
New drug combination for hard-to-treat T-cell lymphoma
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
SuzhouAges 18–75 - NCT05958719RecruitingPhase 2
Chidamide plus chemotherapy for new nodal TFH cell lymphoma
This trial studies whether adding chidamide to a combination chemotherapy plan (azacitidine, liposomal mitoxantrone, and prednisone) works better for people newly diagnosed with nodal T-follicular helper (TFH) cell lymphoma. It’s testing a treatment strategy after diagnosis to improve disease control and outcomes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT07470996Recruiting
T-cell lymphoma treatment after first therapy fails
This trial is for people with certain T-cell lymphomas that did not respond or got worse after initial chemotherapy. It offers a personalized treatment plan, possibly including a stem cell transplant, based on how your disease behaved after first-line therapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07389616RecruitingPhase 2/Phase 3
Preventing lymphoma return after transplant
This trial tests a combination of two drugs (cidabenamine and azacitidine) to help prevent peripheral T-cell lymphoma from coming back after a donor stem cell transplant. It is for patients who are at high risk of progression and have already had a transplant.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06151106RecruitingPhase 2
Study of Chidamide and Duvalisib for Relapsed or Resistant T-Cell Lymphoma
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
Xiamen, FujianAges 18–75 - NCT07356245RecruitingPhase 2
Ruxolitinib after stem cell transplant for T-cell lymphoma
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
Columbus, OhioAges 18 years+ - NCT07353840Recruiting
Personalized treatment for T-cell lymphoma after first complete remission
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07300514RecruitingPhase 3
Golidocitinib vs placebo for T-cell lymphoma maintenance
This trial tests if taking golidocitinib pills after first treatment helps keep peripheral T-cell lymphoma from coming back. You'll either get the study drug or a placebo (no active drug), and your doctor will watch how you do.
ShanghaiAges 18 years+
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Peripheral T Cell Lymphoma trials by city
Studies with a site in or near these metro areas.
Peripheral T Cell Lymphoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for peripheral t cell lymphoma?
- Yes. Clin2 currently lists 243 recruiting peripheral t cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peripheral t cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peripheral t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.